APOC3 and metabolic syndrome: Even though the overexpression of apoCIII has been identified as a crucial factor in the pathogenesis of dyslipidemia, MICT has emerged as an effective tool to normalize the glycemic and lipid profile, as well as hypertensive factors in individuals with dyslipidemia, potentially preventing atherosclerosis.